1,809,408 Shares in ADMA Biologics Inc $ADMA Acquired by Rubric Capital Management LP

Rubric Capital Management LP bought a new position in ADMA Biologics Inc (NASDAQ:ADMA) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,809,408 shares of the biotechnology company’s stock, valued at approximately $16,303,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Calamos Advisors LLC grew its position in shares of ADMA Biologics by 120.0% during the 4th quarter. Calamos Advisors LLC now owns 292,426 shares of the biotechnology company’s stock worth $5,334,000 after buying an additional 159,501 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of ADMA Biologics during the 1st quarter valued at $951,000. BNP Paribas Financial Markets lifted its position in shares of ADMA Biologics by 2,188.4% during the 4th quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company’s stock valued at $20,814,000 after acquiring an additional 1,091,241 shares during the period. Y Intercept Hong Kong Ltd boosted its stake in ADMA Biologics by 1,508.1% during the first quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after acquiring an additional 1,008,548 shares in the last quarter. Finally, Westfield Capital Management Co. LP boosted its stake in ADMA Biologics by 36.9% during the fourth quarter. Westfield Capital Management Co. LP now owns 6,992,907 shares of the biotechnology company’s stock worth $127,551,000 after acquiring an additional 1,886,105 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on ADMA shares. Mizuho decreased their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research note on Thursday, June 18th. Zacks Research upgraded ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.67.

ADMA Biologics Trading Up 2.5%

Shares of ADMA stock opened at $8.48 on Tuesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 12.47 and a beta of 0.73. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $20.46. The company has a 50-day simple moving average of $8.48 and a two-hundred day simple moving average of $11.83.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The firm had revenue of $114.49 million for the quarter, compared to analysts’ expectations of $139.98 million. During the same quarter last year, the firm earned $0.11 EPS. The company’s quarterly revenue was down .3% compared to the same quarter last year. Research analysts anticipate that ADMA Biologics Inc will post 0.8 EPS for the current fiscal year.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Brokerages reportedly maintain a consensus price target of $18.67, substantially above ADMA’s recent trading level. This indicates that analysts see potential upside despite the company’s recent decline from its 52-week high. ADMA Biologics Receives $18.67 Consensus Price Target
• Neutral Sentiment: ADMA’s latest session ended higher and ahead of the market, with trading activity near its normal volume. The report primarily describes the stock’s performance and does not identify a new fundamental catalyst. ADMA Biologics Rises Higher Than Market
• Negative Sentiment: Several law firms publicized a securities class action against ADMA and certain executives, with an August 10, 2026 deadline for investors to seek lead-plaintiff status. The complaints allege misleading statements involving financial condition, revenue recognition, inventory distribution and business practices. These are allegations and have not been proven in court. ADMA Securities Fraud Class Action Alert
• Negative Sentiment: One complaint alleges ADMA shipped unwanted ASCENIV inventory to distributors at $900 per gram, creating artificial demand while payors denied reimbursement and providers reduced orders. If substantiated, the claims could raise concerns about revenue quality, inventory levels, regulatory exposure and potential financial liability. ADMA Shareholder Alert

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman purchased 12,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the acquisition, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.90% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.